Cancer Institute and Hospital, Chinese Academy of Medical Sciences: Carcinoma, Non-Small-Cell Lung trials

The registry lists 29 Carcinoma, Non-Small-Cell Lung studies with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor. 21 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 2Phase 2 11Phase 3 3No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)RecruitingNCT07793500Early Phase 1
• Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC ImmunotherapyRecruitingNCT07668037
• Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor TherapyNot yet recruitingNCT07596524
• Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung CancerNot yet recruitingNCT07560358Phase 3
• Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKINot yet recruitingNCT07551414Phase 2
• A Retrospective Real-World Study Based on RATIONALE-307RecruitingNCT07478809
• An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver MetastasesNot yet recruitingNCT07461727Phase 1
• Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label StudyEnrolling by invitationNCT07373899
• Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLCNot yet recruitingNCT07339839Phase 1/2
• Efficacy of Neoadjuvant Immunotherapy in Patients With Lung CancerRecruitingNCT07166003
• Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLCRecruitingNCT07120282Phase 2
• Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung CancerRecruitingNCT07057102
• Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-ImmunotherapyRecruitingNCT07014202Phase 2
• Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLCRecruitingNCT06897046Phase 2
• Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.Not yet recruitingNCT06452433Phase 2
• Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant ImmunotherapyRecruitingNCT06317558
• The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung CancerRecruitingNCT06287320
• Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)Not yet recruitingNCT06198907Phase 2
• RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNot yet recruitingNCT06185400Phase 2
• Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLCRecruitingNCT05974007
• Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNot yet recruitingNCT04506242Phase 2
• Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant ImmunotherapyActive, not recruitingNCT07256002
• Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLCCompletedNCT07186855
• Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLCCompletedNCT06958614
• Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung CancerActive, not recruitingNCT06540950Phase 2
• Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC TreatmentStatus unknownNCT04970043Not applicable
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene MutationStatus unknownNCT04500717Phase 3
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Phase 3
• Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung CancerStatus unknownNCT01024712Phase 2